Maze Therapeutics (NASDAQ:MAZE) Sees Strong Trading Volume – Here’s Why

Maze Therapeutics, Inc. (NASDAQ:MAZE) saw unusually-strong trading volume on Friday . Approximately 462,051 shares traded hands during mid-day trading, an increase of 52% from the previous session’s volume of 304,540 shares.The stock last traded at $32.72 and had previously closed at $31.84.

Analysts Set New Price Targets

A number of analysts have recently weighed in on the company. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Maze Therapeutics in a research report on Wednesday, October 8th. Raymond James Financial assumed coverage on Maze Therapeutics in a report on Thursday. They set an “outperform” rating and a $48.00 price target on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $50.00 price target on shares of Maze Therapeutics in a research report on Thursday, September 18th. Guggenheim boosted their price objective on Maze Therapeutics from $19.00 to $34.00 and gave the stock a “buy” rating in a research report on Monday, September 15th. Finally, Wedbush upped their target price on shares of Maze Therapeutics from $35.00 to $36.00 and gave the stock an “outperform” rating in a research note on Friday, November 7th. Two research analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Buy” and an average target price of $38.57.

Maze Therapeutics Stock Up 2.4%

The stock has a market capitalization of $1.57 billion and a PE ratio of -1.56. The business’s 50-day moving average is $27.20 and its two-hundred day moving average is $17.85.

Maze Therapeutics (NASDAQ:MAZE) last posted its earnings results on Thursday, November 6th. The company reported ($0.66) EPS for the quarter, topping analysts’ consensus estimates of ($0.74) by $0.08.

Insider Buying and Selling

In other Maze Therapeutics news, Director Richard H. Scheller sold 20,744 shares of the business’s stock in a transaction that occurred on Monday, September 15th. The stock was sold at an average price of $22.37, for a total value of $464,043.28. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of MAZE. TRV GP IV LLC purchased a new position in shares of Maze Therapeutics during the first quarter worth about $66,874,000. Frazier Life Sciences Management L.P. acquired a new position in Maze Therapeutics in the 1st quarter valued at $45,460,000. ARCH Venture Management LLC purchased a new position in Maze Therapeutics during the 1st quarter worth $45,362,000. Matrix Capital Management Company LP acquired a new position in Maze Therapeutics during the 1st quarter worth approximately $27,373,000. Finally, TRV GP V LLC purchased a new position in shares of Maze Therapeutics during the 1st quarter worth approximately $10,468,000.

Maze Therapeutics Company Profile

We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization.